Markowitz Glen S, Schwimmer Joshua A, Stokes M Barry, Nasr Samih, Seigle Robert L, Valeri Anthony M, D'Agati Vivette D
Department of Pathology, Columbia University,College of Physicians & Surgeons, New York, New York 10032, USA.
Kidney Int. 2003 Oct;64(4):1232-40. doi: 10.1046/j.1523-1755.2003.00218.x.
C1q nephropathy is a poorly understood and controversial entity with distinctive immunopathologic features. In order to better define the clinical-pathologic spectrum, we report the largest single-center series.
Nineteen biopsies with C1q nephropathy were identified from among 8909 native kidney biopsies received from 1994 to 2002 (0.21%). Defining criteria included (1). dominant or co-dominant immunofluorescence staining for C1q, (2). mesangial electron dense deposits, and (3). no clinical or serologic evidence of systemic lupus erythematosus (SLE).
The 19 patients were predominantly African American (73.7%), female (73.7%), young adults and children (range, 3 to 42 years; mean, 24.2 years). Presentation included nephrotic range proteinuria (78.9%), nephrotic syndrome (50%), renal insufficiency (27.8%), and hematuria (22.2%). No patient had hypocomplementemia or evidence of underlying autoimmune or infectious disease. Renal biopsy revealed focal segmental glomerulosclerosis (FSGS) in 17 (including six collapsing and two cellular) and minimal-change disease (MCD) in two. All biopsies displayed co-deposits of immunoglobulin G (IgG), with more variable IgM (84.2%), IgA (31.6%), and C3 (52.6%). Foot process effacement varied from 20% to 100% (mean, 51%). Twelve of 16 patients with available follow-up received immunosuppressive therapy. One patient had complete remission of proteinuria and six had partial remission. Four patients with FSGS pattern had progressive renal insufficiency, including two who reached end-stage renal disease (ESRD). Median time from biopsy to ESRD was 81 months. On multivariate analysis, the best correlate of renal insufficiency at biopsy and at follow-up was the degree of tubular atrophy and interstitial fibrosis (P = 0.0495 and 0.0341, respectively).
C1q nephropathy falls within the clinical-pathologic spectrum of MCD/FSGS. Although further studies are needed to determine the pathomechanism of C1q deposition, we hypothesize that it may be a non-specific marker of increased mesangial trafficking in the setting of glomerular proteinuria.
C1q肾病是一种了解甚少且存在争议的疾病实体,具有独特的免疫病理特征。为了更好地界定其临床病理谱,我们报告了最大的单中心系列研究。
在1994年至2002年接收的8909例肾活检中,确定了19例C1q肾病活检病例(0.21%)。定义标准包括:(1)C1q呈显性或共显性免疫荧光染色;(2)系膜区电子致密沉积物;(3)无系统性红斑狼疮(SLE)的临床或血清学证据。
19例患者以非裔美国人为主(73.7%),女性(73.7%),为年轻人和儿童(年龄范围3至42岁;平均24.2岁)。临床表现包括肾病范围蛋白尿(78.9%)、肾病综合征(50%)、肾功能不全(27.8%)和血尿(22.2%)。无患者有补体低下或潜在自身免疫或感染性疾病的证据。肾活检显示17例为局灶节段性肾小球硬化(FSGS)(包括6例塌陷型和2例细胞型),2例为微小病变肾病(MCD)。所有活检均显示免疫球蛋白G(IgG)共沉积,IgM(84.2%)、IgA(31.6%)和C3(52.6%)的沉积情况变化更大。足突消失率从20%至100%不等(平均51%)。16例有随访资料的患者中,12例接受了免疫抑制治疗。1例患者蛋白尿完全缓解,6例部分缓解。4例FSGS型患者出现进行性肾功能不全,其中2例进展至终末期肾病(ESRD)。从活检到ESRD的中位时间为81个月。多因素分析显示,活检时和随访时肾功能不全的最佳相关因素是肾小管萎缩和间质纤维化程度(分别为P = 0.0495和0.0341)。
C1q肾病属于MCD/FSGS的临床病理谱。虽然需要进一步研究以确定C1q沉积的发病机制,但我们推测它可能是肾小球蛋白尿情况下系膜转运增加的非特异性标志物。